Serum neurofilament light chain as a reliable biomarker of hereditary transthyretin‐related amyloidosis—A Swiss reference center experience
Hereditary transthyretin‐related (hATTR) amyloidosis is a rare disease, causing a disabling and life‐threatening axonal length‐dependent polyneuropathy. Monitoring of disease progression and treatment response is difficult. We aimed to determine if serum neurofilament light chain (sNfL) is a reliabl...
Uložené v:
| Vydané v: | Journal of the peripheral nervous system Ročník 28; číslo 1; s. 86 - 97 |
|---|---|
| Hlavní autori: | , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
Malden, USA
Wiley Periodicals, Inc
01.03.2023
Wiley Subscription Services, Inc |
| Predmet: | |
| ISSN: | 1085-9489, 1529-8027, 1529-8027 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Hereditary transthyretin‐related (hATTR) amyloidosis is a rare disease, causing a disabling and life‐threatening axonal length‐dependent polyneuropathy. Monitoring of disease progression and treatment response is difficult. We aimed to determine if serum neurofilament light chain (sNfL) is a reliable and early biomarker of peripheral neuropathy in hATTR amyloidosis. We prospectively included 20 hATTR patients, 14 symptomatic and 6 asymptomatic. Patients were assessed at baseline and 1 year, including a full clinical examination with disease severity and functional scores, electrochemical skin conductance measurement with Sudoscan and nerve conduction studies, and sNfL level. hATTR patient sNfL were also compared with sNfL of 4532 healthy controls of a reference database by calculating age and BMI‐adjusted Z scores. At baseline, median sNfL concentration was 3.6‐fold higher in symptomatic than asymptomatic hATTR patients (P = .003), and this difference was also found in our under 60‐years‐old patients (P = .003). There was no significant difference of sNfL concentration between asymptomatic patients and healthy controls (Z‐score of −0.29), but a significant difference between symptomatic patients and healthy controls (Z‐score of 2.52). We found a significant correlation between sNfL levels and most clinical and electrophysiological disease severity scores, the strongest correlation being with the NIS score. sNfL seems to be a reliable biomarker of peripheral neuropathy severity in hATTR amyloidosis and can distinguish between asymptomatic and symptomatic patients. sNfL could also become a reliable biomarker to establish disease onset and treatment response. |
|---|---|
| AbstractList | Hereditary transthyretin‐related (hATTR) amyloidosis is a rare disease, causing a disabling and life‐threatening axonal length‐dependent polyneuropathy. Monitoring of disease progression and treatment response is difficult. We aimed to determine if serum neurofilament light chain (sNfL) is a reliable and early biomarker of peripheral neuropathy in hATTR amyloidosis. We prospectively included 20 hATTR patients, 14 symptomatic and 6 asymptomatic. Patients were assessed at baseline and 1 year, including a full clinical examination with disease severity and functional scores, electrochemical skin conductance measurement with Sudoscan and nerve conduction studies, and sNfL level. hATTR patient sNfL were also compared with sNfL of 4532 healthy controls of a reference database by calculating age and BMI‐adjusted Z scores. At baseline, median sNfL concentration was 3.6‐fold higher in symptomatic than asymptomatic hATTR patients (P = .003), and this difference was also found in our under 60‐years‐old patients (P = .003). There was no significant difference of sNfL concentration between asymptomatic patients and healthy controls (Z‐score of −0.29), but a significant difference between symptomatic patients and healthy controls (Z‐score of 2.52). We found a significant correlation between sNfL levels and most clinical and electrophysiological disease severity scores, the strongest correlation being with the NIS score. sNfL seems to be a reliable biomarker of peripheral neuropathy severity in hATTR amyloidosis and can distinguish between asymptomatic and symptomatic patients. sNfL could also become a reliable biomarker to establish disease onset and treatment response. Hereditary transthyretin‐related (hATTR) amyloidosis is a rare disease, causing a disabling and life‐threatening axonal length‐dependent polyneuropathy. Monitoring of disease progression and treatment response is difficult. We aimed to determine if serum neurofilament light chain (sNfL) is a reliable and early biomarker of peripheral neuropathy in hATTR amyloidosis. We prospectively included 20 hATTR patients, 14 symptomatic and 6 asymptomatic. Patients were assessed at baseline and 1 year, including a full clinical examination with disease severity and functional scores, electrochemical skin conductance measurement with Sudoscan and nerve conduction studies, and sNfL level. hATTR patient sNfL were also compared with sNfL of 4532 healthy controls of a reference database by calculating age and BMI‐adjusted Z scores. At baseline, median sNfL concentration was 3.6‐fold higher in symptomatic than asymptomatic hATTR patients ( P = .003), and this difference was also found in our under 60‐years‐old patients ( P = .003). There was no significant difference of sNfL concentration between asymptomatic patients and healthy controls (Z‐score of −0.29), but a significant difference between symptomatic patients and healthy controls (Z‐score of 2.52). We found a significant correlation between sNfL levels and most clinical and electrophysiological disease severity scores, the strongest correlation being with the NIS score. sNfL seems to be a reliable biomarker of peripheral neuropathy severity in hATTR amyloidosis and can distinguish between asymptomatic and symptomatic patients. sNfL could also become a reliable biomarker to establish disease onset and treatment response. Hereditary transthyretin-related (hATTR) amyloidosis is a rare disease, causing a disabling and life-threatening axonal length-dependent polyneuropathy. Monitoring of disease progression and treatment response is difficult. We aimed to determine if serum neurofilament light chain (sNfL) is a reliable and early biomarker of peripheral neuropathy in hATTR amyloidosis. We prospectively included 20 hATTR patients, 14 symptomatic and 6 asymptomatic. Patients were assessed at baseline and 1 year, including a full clinical examination with disease severity and functional scores, electrochemical skin conductance measurement with Sudoscan and nerve conduction studies, and sNfL level. hATTR patient sNfL were also compared with sNfL of 4532 healthy controls of a reference database by calculating age and BMI-adjusted Z scores. At baseline, median sNfL concentration was 3.6-fold higher in symptomatic than asymptomatic hATTR patients (P = .003), and this difference was also found in our under 60-years-old patients (P = .003). There was no significant difference of sNfL concentration between asymptomatic patients and healthy controls (Z-score of -0.29), but a significant difference between symptomatic patients and healthy controls (Z-score of 2.52). We found a significant correlation between sNfL levels and most clinical and electrophysiological disease severity scores, the strongest correlation being with the NIS score. sNfL seems to be a reliable biomarker of peripheral neuropathy severity in hATTR amyloidosis and can distinguish between asymptomatic and symptomatic patients. sNfL could also become a reliable biomarker to establish disease onset and treatment response. Hereditary transthyretin‐related (hATTR) amyloidosis is a rare disease, causing a disabling and life‐threatening axonal length‐dependent polyneuropathy. Monitoring of disease progression and treatment response is difficult. We aimed to determine if serum neurofilament light chain (sNfL) is a reliable and early biomarker of peripheral neuropathy in hATTR amyloidosis. We prospectively included 20 hATTR patients, 14 symptomatic and 6 asymptomatic. Patients were assessed at baseline and 1 year, including a full clinical examination with disease severity and functional scores, electrochemical skin conductance measurement with Sudoscan and nerve conduction studies, and sNfL level. hATTR patient sNfL were also compared with sNfL of 4532 healthy controls of a reference database by calculating age and BMI‐adjusted Z scores. At baseline, median sNfL concentration was 3.6‐fold higher in symptomatic than asymptomatic hATTR patients (P = .003), and this difference was also found in our under 60‐years‐old patients (P = .003). There was no significant difference of sNfL concentration between asymptomatic patients and healthy controls (Z‐score of −0.29), but a significant difference between symptomatic patients and healthy controls (Z‐score of 2.52). We found a significant correlation between sNfL levels and most clinical and electrophysiological disease severity scores, the strongest correlation being with the NIS score. sNfL seems to be a reliable biomarker of peripheral neuropathy severity in hATTR amyloidosis and can distinguish between asymptomatic and symptomatic patients. sNfL could also become a reliable biomarker to establish disease onset and treatment response. Hereditary transthyretin-related (hATTR) amyloidosis is a rare disease, causing a disabling and life-threatening axonal length-dependent polyneuropathy. Monitoring of disease progression and treatment response is difficult. We aimed to determine if serum neurofilament light chain (sNfL) is a reliable and early biomarker of peripheral neuropathy in hATTR amyloidosis. We prospectively included 20 hATTR patients, 14 symptomatic and 6 asymptomatic. Patients were assessed at baseline and 1 year, including a full clinical examination with disease severity and functional scores, electrochemical skin conductance measurement with Sudoscan and nerve conduction studies, and sNfL level. hATTR patient sNfL were also compared with sNfL of 4532 healthy controls of a reference database by calculating age and BMI-adjusted Z scores. At baseline, median sNfL concentration was 3.6-fold higher in symptomatic than asymptomatic hATTR patients (P = .003), and this difference was also found in our under 60-years-old patients (P = .003). There was no significant difference of sNfL concentration between asymptomatic patients and healthy controls (Z-score of -0.29), but a significant difference between symptomatic patients and healthy controls (Z-score of 2.52). We found a significant correlation between sNfL levels and most clinical and electrophysiological disease severity scores, the strongest correlation being with the NIS score. sNfL seems to be a reliable biomarker of peripheral neuropathy severity in hATTR amyloidosis and can distinguish between asymptomatic and symptomatic patients. sNfL could also become a reliable biomarker to establish disease onset and treatment response.Hereditary transthyretin-related (hATTR) amyloidosis is a rare disease, causing a disabling and life-threatening axonal length-dependent polyneuropathy. Monitoring of disease progression and treatment response is difficult. We aimed to determine if serum neurofilament light chain (sNfL) is a reliable and early biomarker of peripheral neuropathy in hATTR amyloidosis. We prospectively included 20 hATTR patients, 14 symptomatic and 6 asymptomatic. Patients were assessed at baseline and 1 year, including a full clinical examination with disease severity and functional scores, electrochemical skin conductance measurement with Sudoscan and nerve conduction studies, and sNfL level. hATTR patient sNfL were also compared with sNfL of 4532 healthy controls of a reference database by calculating age and BMI-adjusted Z scores. At baseline, median sNfL concentration was 3.6-fold higher in symptomatic than asymptomatic hATTR patients (P = .003), and this difference was also found in our under 60-years-old patients (P = .003). There was no significant difference of sNfL concentration between asymptomatic patients and healthy controls (Z-score of -0.29), but a significant difference between symptomatic patients and healthy controls (Z-score of 2.52). We found a significant correlation between sNfL levels and most clinical and electrophysiological disease severity scores, the strongest correlation being with the NIS score. sNfL seems to be a reliable biomarker of peripheral neuropathy severity in hATTR amyloidosis and can distinguish between asymptomatic and symptomatic patients. sNfL could also become a reliable biomarker to establish disease onset and treatment response. |
| Author | Pasquier, Jérôme Maceski, Aleksandra Vicino, Alex Loser, Valentin Kuntzer, Thierry Kuhle, Jens Lim Dubois Ferriere, Pansy Theaudin, Marie Benkert, Pascal |
| Author_xml | – sequence: 1 givenname: Valentin orcidid: 0000-0002-2609-6843 surname: Loser fullname: Loser, Valentin email: valentin.loser@chuv.ch organization: Lausanne University Hospital and University of Lausanne – sequence: 2 givenname: Pascal surname: Benkert fullname: Benkert, Pascal organization: University Hospital and University of Basel – sequence: 3 givenname: Alex surname: Vicino fullname: Vicino, Alex organization: Lausanne University Hospital and University of Lausanne – sequence: 4 givenname: Pansy surname: Lim Dubois Ferriere fullname: Lim Dubois Ferriere, Pansy organization: Lausanne University Hospital and University of Lausanne – sequence: 5 givenname: Thierry surname: Kuntzer fullname: Kuntzer, Thierry organization: Lausanne University Hospital and University of Lausanne – sequence: 6 givenname: Jérôme surname: Pasquier fullname: Pasquier, Jérôme organization: University of Lausanne – sequence: 7 givenname: Aleksandra surname: Maceski fullname: Maceski, Aleksandra organization: University Hospital and University of Basel – sequence: 8 givenname: Jens surname: Kuhle fullname: Kuhle, Jens organization: University Hospital and University of Basel – sequence: 9 givenname: Marie surname: Theaudin fullname: Theaudin, Marie organization: Lausanne University Hospital and University of Lausanne |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36471582$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kctu1DAYhS1URC-w4AWQJTawSBs7dpwsq6rcVMFiYG05zh_Gg2MPdqKSXd8AFjxhn4S_zHRTgTe-6DvH9jnH5CDEAIQ8Z-Upw3G2CfmUccnFI3LEJG-LpuTqANdlI4tWNO0hOc55U5ZMtax9Qg6rWigmG35Efq4gzSMNMKc4OG9GCBP17ut6onZtXKAmU0MTeGc6D7RzcTTpGyQaB7qGBL2bTFrolEzI03pJMLlwe_MLBWaCnppx8dH1Mbt8e_P7nK6uXc5oN6A0WKAWr0Mz-LGF5O5OnpLHg_EZnu3nE_LlzeXni3fF1ae37y_OrwpbyUoUwg5ssFK21nD8jGhwC3UjWTWYWnUWWsuUZa3goBo1yK7rqpoPddWC4Zb11Ql5tfPdpvh9hjzp0WUL3psAcc6aK6G4UlIIRF8-QDdxTgFfh1TDRF3LukLqxZ6auxF6vU0Ok1r0fdQInO0Am2LOGIG2mN3kYsDwnNes1HdlaixT_y0TFa8fKO5N_8Xu3a-dh-X_oP7wcbVT_AE7_LLv |
| CitedBy_id | crossref_primary_10_1007_s40120_024_00696_5 crossref_primary_10_1038_s41598_023_50212_2 crossref_primary_10_1515_dx_2025_0042 crossref_primary_10_1080_13506129_2024_2409760 crossref_primary_10_1007_s10072_024_07311_3 crossref_primary_10_1007_s10072_025_08110_0 crossref_primary_10_1007_s00415_025_13072_6 crossref_primary_10_1080_13506129_2023_2289340 crossref_primary_10_1111_ene_16070 crossref_primary_10_1007_s10072_024_07562_0 crossref_primary_10_1080_13506129_2024_2327342 crossref_primary_10_1038_s41598_024_60025_6 crossref_primary_10_3390_ijms25073770 crossref_primary_10_1080_17474086_2024_2388184 crossref_primary_10_1080_13506129_2024_2313218 crossref_primary_10_1177_22143602241284130 crossref_primary_10_1111_jns_12608 |
| Cites_doi | 10.1517/14656566.2016.1145664 10.1212/WNL.36.11.1413 10.1002/mus.20821 10.3109/13506129.2012.685665 10.1016/0140-6736(93)93127-M 10.1038/s41467-020-14612-6 10.1212/WNL.0000000000011090 10.1111/jns.12128 10.1056/NEJMoa1716793 10.1007/s00415-007-0617-5 10.1016/j.jns.2020.116776 10.1111/jns.12350 10.1159/000052074 10.1136/annrheumdis-2017-212045 10.1080/13506129.2020.1815696 10.1212/WNL.0b013e318208824b 10.1080/13506129.2018.1531842 10.1212/WNL.0000000000004932 10.1016/S1474-4422(22)00009-6 10.1080/13506129.2019.1627312 10.1097/WCO.0000000000000290 10.1111/j.1600-6143.2007.01969.x 10.1089/dia.2005.7.497 10.1080/13506129.2019.1708716 10.1002/ana.26004 10.1056/NEJMoa1716153 10.1177/1352458519885613 10.1212/NXI.0000000000000555 |
| ContentType | Journal Article |
| Copyright | 2022 Peripheral Nerve Society. 2023 Peripheral Nerve Society. |
| Copyright_xml | – notice: 2022 Peripheral Nerve Society. – notice: 2023 Peripheral Nerve Society. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7TK K9. 7X8 |
| DOI | 10.1111/jns.12524 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Neurosciences Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) Neurosciences Abstracts MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 1529-8027 |
| EndPage | 97 |
| ExternalDocumentID | 36471582 10_1111_jns_12524 JNS12524 |
| Genre | caseStudy Case Reports |
| GeographicLocations | Switzerland |
| GeographicLocations_xml | – name: Switzerland |
| GroupedDBID | --- .3N .GA .Y3 05W 0R~ 10A 1OC 29L 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 6PF 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANHP AANLZ AAONW AASGY AAWTL AAXRX AAYCA AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACUHS ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG CO8 COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EAD EAP EAS EBC EBD EBS EJD EMB EMK EMOBN ENC EPT ESX EX3 F00 F01 F04 F5P FEDTE FUBAC G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PQQKQ Q.N Q11 QB0 Q~Q R.K ROL RX1 SUPJJ SV3 TEORI TUS UB1 W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WVDHM WXI WXSBR XG1 YFH ZZTAW ~IA ~WT AAMMB AAYXX AEFGJ AGHNM AGQPQ AGXDD AGYGG AIDQK AIDYY CITATION O8X CGR CUY CVF ECM EIF NPM 7TK K9. 7X8 |
| ID | FETCH-LOGICAL-c3534-4cf1fc559ca236448f1fe68513fa67bce9c17c1942e787f5bbb362f639ea2c1d3 |
| IEDL.DBID | DRFUL |
| ISICitedReferencesCount | 20 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000896908700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1085-9489 1529-8027 |
| IngestDate | Thu Oct 02 06:40:15 EDT 2025 Sat Nov 29 14:52:11 EST 2025 Wed Feb 19 02:24:27 EST 2025 Sat Nov 29 05:28:34 EST 2025 Tue Nov 18 22:25:43 EST 2025 Wed Jan 22 16:14:53 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | amyloidosis neurofilament light chain biomarker disease severity ATTR |
| Language | English |
| License | 2022 Peripheral Nerve Society. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3534-4cf1fc559ca236448f1fe68513fa67bce9c17c1942e787f5bbb362f639ea2c1d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Case Study-2 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3 |
| ORCID | 0000-0002-2609-6843 |
| PMID | 36471582 |
| PQID | 2781466563 |
| PQPubID | 1086377 |
| PageCount | 12 |
| ParticipantIDs | proquest_miscellaneous_2747277544 proquest_journals_2781466563 pubmed_primary_36471582 crossref_citationtrail_10_1111_jns_12524 crossref_primary_10_1111_jns_12524 wiley_primary_10_1111_jns_12524_JNS12524 |
| PublicationCentury | 2000 |
| PublicationDate | March 2023 2023-03-00 20230301 |
| PublicationDateYYYYMMDD | 2023-03-01 |
| PublicationDate_xml | – month: 03 year: 2023 text: March 2023 |
| PublicationDecade | 2020 |
| PublicationPlace | Malden, USA |
| PublicationPlace_xml | – name: Malden, USA – name: United States – name: La Jolla |
| PublicationTitle | Journal of the peripheral nervous system |
| PublicationTitleAlternate | J Peripher Nerv Syst |
| PublicationYear | 2023 |
| Publisher | Wiley Periodicals, Inc Wiley Subscription Services, Inc |
| Publisher_xml | – name: Wiley Periodicals, Inc – name: Wiley Subscription Services, Inc |
| References | 2019; 6 2021; 89 2021; 28 1986; 36 2012; 19 2011; 76 1999; 41 1999; 122 2022; 21 2020; 11 2016; 17 2021; 96 1993; 341 2007; 36 2018; 25 2022 2019; 24 2015; 20 2007; 254 2018; 379 2019; 26 2020; 413 2020; 27 2020; 26 2018; 90 2005; 7 2007; 7 1980 2016; 29 2018; 77 1949 e_1_2_7_6_1 e_1_2_7_4_1 e_1_2_7_3_1 e_1_2_7_9_1 e_1_2_7_8_1 e_1_2_7_7_1 e_1_2_7_19_1 e_1_2_7_18_1 e_1_2_7_17_1 e_1_2_7_16_1 e_1_2_7_2_1 e_1_2_7_15_1 e_1_2_7_14_1 e_1_2_7_13_1 e_1_2_7_12_1 Coutinho P (e_1_2_7_24_1) 1980 e_1_2_7_11_1 e_1_2_7_10_1 e_1_2_7_27_1 e_1_2_7_28_1 e_1_2_7_29_1 Karnofsky D (e_1_2_7_26_1) 1949 Berends M (e_1_2_7_33_1) 2022 e_1_2_7_30_1 e_1_2_7_25_1 e_1_2_7_31_1 Misu K (e_1_2_7_5_1) 1999; 122 e_1_2_7_32_1 e_1_2_7_23_1 e_1_2_7_22_1 e_1_2_7_21_1 e_1_2_7_20_1 Aldinc E (e_1_2_7_34_1) 2022 |
| References_xml | – volume: 27 start-page: 97 issue: 2 year: 2020 end-page: 102 article-title: Plasma neurofilament light chain: an early biomarker for hereditary ATTR amyloid polyneuropathy publication-title: Amyloid – volume: 6 issue: 3 year: 2019 article-title: Profiling individual clinical responses by high‐frequency serum neurofilament assessment in MS publication-title: Neurol Neuroimmunol Neuroinflammation – volume: 7 start-page: 2597 issue: 11 year: 2007 end-page: 2604 article-title: Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single‐center experience over 16 years publication-title: Am J Transplant – volume: 379 start-page: 11 issue: 1 year: 2018 end-page: 21 article-title: Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis publication-title: N Engl J Med – volume: 20 start-page: 333 issue: 3 year: 2015 end-page: 340 article-title: Improving assessment in small fiber neuropathy publication-title: J Peripher Nerv Syst – volume: 17 start-page: 791 issue: 6 year: 2016 end-page: 802 article-title: TTR kinetic stabilizers and TTR gene silencing: a new era in therapy for familial amyloidotic polyneuropathies publication-title: Expert Opin Pharmacother – volume: 341 start-page: 1113 year: 1993 end-page: 1116 article-title: Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis publication-title: Lancet – volume: 24 start-page: 314 issue: 4 year: 2019 end-page: 319 article-title: Plasma neurofilament light chain concentration is increased and correlates with the severity of neuropathy in hereditary transthyretin amyloidosis publication-title: J Peripher Nerv Syst – volume: 36 start-page: 1413 issue: 11 year: 1986 end-page: 1417 article-title: Genetic expression of a transthyretin mutation in typical and late‐onset Portuguese families with familial amyloidotic polyneuropathy publication-title: Neurology – volume: 96 start-page: e412 issue: 3 year: 2021 end-page: e422 article-title: Neurofilament light chain as a biomarker of hereditary transthyretin‐mediated amyloidosis publication-title: Neurology – volume: 7 start-page: 497 issue: 3 year: 2005 end-page: 508 article-title: The development and validation of the Norfolk QOL‐DN, a new measure of patients' perception of the effects of diabetes and diabetic neuropathy publication-title: Diabetes Technol Ther – volume: 77 start-page: 1093 issue: 7 year: 2018 end-page: 1094 article-title: Serum neurofilament light chain: a biomarker of neuronal injury in vasculitic neuropathy publication-title: Ann Rheum Dis – volume: 89 start-page: 610 issue: 3 year: 2021 end-page: 616 article-title: Serum neurofilament light chain levels in the intensive care unit: comparison between severely ill patients with and without coronavirus disease 2019 publication-title: Ann Neurol – volume: 122 start-page: 1951 issue: 10 year: 1999 end-page: 1962 article-title: Late‐onset familial amyloid polyneuropathy type I (transthyretin Met30‐associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan. Clinicopathological and genetic features. Brain publication-title: J Neurol – volume: 379 start-page: 22 issue: 1 year: 2018 end-page: 31 article-title: Inotersen treatment for patients with hereditary transthyretin amyloidosis publication-title: N Engl J Med – start-page: 191 year: 1949 end-page: 205 – volume: 11 start-page: 812 issue: 1 year: 2020 article-title: Serum neurofilament light levels in normal aging and their association with morphologic brain changes publication-title: Nat Commun – volume: 28 start-page: 50 issue: 1 year: 2021 end-page: 55 article-title: Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis publication-title: Amyloid – volume: 413 year: 2020 article-title: Follow‐up in transthyretin familial amyloid polyneuropathy: useful investigations publication-title: J Neurol Sci – volume: 21 start-page: 246 issue: 3 year: 2022 end-page: 257 article-title: Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study publication-title: Lancet Neurol – start-page: 88 year: 1980 end-page: 98 – volume: 26 start-page: 1691 issue: 13 year: 2020 end-page: 1699 article-title: Neurofilament light levels are associated with long‐term outcomes in multiple sclerosis publication-title: Mult Scler – volume: 254 start-page: 1684 issue: 12 year: 2007 end-page: 1688 article-title: A brief compound test for assessment of autonomic and sensory‐motor dysfunction in familial amyloid polyneuropathy publication-title: J Neurol – volume: 26 start-page: 103 issue: 3 year: 2019 end-page: 111 article-title: Assessment of patients with hereditary transthyretin amyloidosis ‐ understanding the impact of management and disease progression publication-title: Amyloid – volume: 36 start-page: 411 year: 2007 end-page: 423 article-title: The molecular biology and clinical features of amyloid neuropathy publication-title: Muscle Nerve – volume: 25 start-page: 143 issue: 3 year: 2018 end-page: 147 article-title: Origin of sporadic late‐onset hereditary ATTR Val30Met amyloidosis in Japan publication-title: Amyloid – volume: 29 start-page: S27 issue: Suppl 1 year: 2016 end-page: S35 article-title: Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis publication-title: Curr Opin Neurol – year: 2022 – volume: 76 start-page: 337 issue: 4 year: 2011 end-page: 345 article-title: Rasch‐built overall disability scale (R‐ODS) for immune‐mediated peripheral neuropathies publication-title: Neurology – volume: 90 start-page: e518 issue: 6 year: 2018 end-page: e524 article-title: Plasma neurofilament light chain concentration in the inherited peripheral neuropathies publication-title: Neurology – volume: 19 start-page: 61 issue: Suppl 1 year: 2012 end-page: 64 article-title: Regional difference and similarity of familial amyloidosis with polyneuropathy in France publication-title: Amyloid – volume: 41 start-page: 8 issue: Suppl 1 year: 1999 end-page: 13 article-title: NIS‐LL: the primary measurement scale for clinical trial endpoints in diabetic peripheral neuropathy publication-title: Eur Neurol – ident: e_1_2_7_8_1 doi: 10.1517/14656566.2016.1145664 – start-page: 88 volume-title: Amyloid and Amyloidosis year: 1980 ident: e_1_2_7_24_1 – ident: e_1_2_7_4_1 doi: 10.1212/WNL.36.11.1413 – ident: e_1_2_7_2_1 doi: 10.1002/mus.20821 – start-page: 191 volume-title: The Clinical Evaluation of Chemotherapeutic Agents in Cancer year: 1949 ident: e_1_2_7_26_1 – volume: 122 start-page: 1951 issue: 10 year: 1999 ident: e_1_2_7_5_1 article-title: Late‐onset familial amyloid polyneuropathy type I (transthyretin Met30‐associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan. Clinicopathological and genetic features. Brain publication-title: J Neurol – ident: e_1_2_7_6_1 doi: 10.3109/13506129.2012.685665 – ident: e_1_2_7_7_1 doi: 10.1016/0140-6736(93)93127-M – ident: e_1_2_7_31_1 doi: 10.1038/s41467-020-14612-6 – ident: e_1_2_7_18_1 doi: 10.1212/WNL.0000000000011090 – ident: e_1_2_7_20_1 doi: 10.1111/jns.12128 – ident: e_1_2_7_10_1 doi: 10.1056/NEJMoa1716793 – ident: e_1_2_7_21_1 doi: 10.1007/s00415-007-0617-5 – ident: e_1_2_7_32_1 doi: 10.1016/j.jns.2020.116776 – ident: e_1_2_7_15_1 doi: 10.1111/jns.12350 – ident: e_1_2_7_22_1 doi: 10.1159/000052074 – ident: e_1_2_7_13_1 doi: 10.1136/annrheumdis-2017-212045 – ident: e_1_2_7_17_1 doi: 10.1080/13506129.2020.1815696 – volume-title: Poster Session Presented at: XVIII Meeting of the International Society of Amylodosis (ISA) year: 2022 ident: e_1_2_7_33_1 – ident: e_1_2_7_25_1 doi: 10.1212/WNL.0b013e318208824b – ident: e_1_2_7_3_1 doi: 10.1080/13506129.2018.1531842 – ident: e_1_2_7_14_1 doi: 10.1212/WNL.0000000000004932 – ident: e_1_2_7_19_1 doi: 10.1016/S1474-4422(22)00009-6 – ident: e_1_2_7_28_1 doi: 10.1080/13506129.2019.1627312 – ident: e_1_2_7_11_1 doi: 10.1097/WCO.0000000000000290 – ident: e_1_2_7_23_1 doi: 10.1111/j.1600-6143.2007.01969.x – ident: e_1_2_7_27_1 doi: 10.1089/dia.2005.7.497 – ident: e_1_2_7_16_1 doi: 10.1080/13506129.2019.1708716 – ident: e_1_2_7_30_1 doi: 10.1002/ana.26004 – volume-title: Poster Session Presented at: XVIII Meeting of the International Society of Amylodosis (ISA) year: 2022 ident: e_1_2_7_34_1 – ident: e_1_2_7_9_1 doi: 10.1056/NEJMoa1716153 – ident: e_1_2_7_12_1 doi: 10.1177/1352458519885613 – ident: e_1_2_7_29_1 doi: 10.1212/NXI.0000000000000555 |
| SSID | ssj0017919 |
| Score | 2.4380214 |
| Snippet | Hereditary transthyretin‐related (hATTR) amyloidosis is a rare disease, causing a disabling and life‐threatening axonal length‐dependent polyneuropathy.... Hereditary transthyretin-related (hATTR) amyloidosis is a rare disease, causing a disabling and life-threatening axonal length-dependent polyneuropathy.... |
| SourceID | proquest pubmed crossref wiley |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 86 |
| SubjectTerms | Amyloid Neuropathies, Familial - diagnosis Amyloidosis Asymptomatic ATTR biomarker Biomarkers disease severity Humans Intermediate Filaments Middle Aged Nerve conduction neurofilament light chain Neurofilament Proteins Patients Peripheral neuropathy Polyneuropathy Prealbumin Switzerland Transthyretin |
| Title | Serum neurofilament light chain as a reliable biomarker of hereditary transthyretin‐related amyloidosis—A Swiss reference center experience |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fjns.12524 https://www.ncbi.nlm.nih.gov/pubmed/36471582 https://www.proquest.com/docview/2781466563 https://www.proquest.com/docview/2747277544 |
| Volume | 28 |
| WOSCitedRecordID | wos000896908700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library Full Collection 2020 customDbUrl: eissn: 1529-8027 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017919 issn: 1085-9489 databaseCode: DRFUL dateStart: 20000101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1fa9RAEB_aq4gv_mnVntYyiogvgWaz-bP4dKiHSD3EWri3sNns0sBdIpe7St_6DfTBT9hP4sxeLlhUEHxLyCQ7ZGd2ZnZnfgPw3Cbcz8HEgSgFBSjK6EBrp4OyjIVRTtGa6QuFj9PJJJtO1ccteLWphVnjQ_QbbqwZfr1mBddF-6uS06SQdRZyG3YEyW08gJ03n8anx_0hQqp8Xw-fX69kpjpgIZ_Is3n5ujn6zce87rJ6mzO-81_c3oXbnauJo7Vs3IMtW-_C3qimMHt-gS_QJ3_6XfVduPmhO2Pfg2-0fKzm6IEuXUUCQ2YJZxzDoznTVY26RY0L4oerrpDr9znFZ4GNwzPu_FktiU1cshEkKeAqyfrq8rsvmrEl6vnFrKnKpq3aq8sfIzz5SlOPfbcT5GxR-pjtIZjvw-n47efX74KubUNgojiSgTQudIYiFaMZnV5mdGsT8uwip5O0MFaZMDWhksLSauHioihIIhy5SlYLE5bRAxjUTW33AZUrlYzjqLCZkoqC9UgmkbOFc0lWHpl0CC83s5ebDtOcW2vM8j62qdvc__chPOtJv6yBPP5EdLARgbzT5TYXjAqWkN8bDeFp_5i0kI9WdG2bFdNIcgQZTHAID9ei04_CCP1hnAli1kvI34fP309O_MWjfyd9DLcE-V3rtLgDGCwXK_sEbpjzZdUuDmE7nWaHnWL8BPHSFSM |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1fa9RAEB9qK-pL1dbq1aqjiPgSaJLNnwVfDvWoej3EttC3sNns0sBdIpc7pW_9BvrgJ-wncWaTCxYVBN8Sssku2d_szOzO_AbguYm5noOOvKAIyEGRWnlKWeUVRRRoaSWtmS5ReJxMJunpqfy4Bq9WuTAtP0S_4caS4dZrFnDekP5VymlWSD0H4hpsCIIR4XvjzafRybg_RUikK-zhAuylSGXHLOQieVYvX9VHvxmZV21Wp3RGt_9vuHdgszM2cdii4y6smWoLtocVOdqzc3yBLvzT7atvwY3D7pR9G77RArKcoaO6tCVBhhQTTtmLR32mygpVgwrnNCDOu0LO4OcgnznWFs-49me5oHHigtUg4YDzJKvLi-8ubcYUqGbn07os6qZsLi9-DPHoK00-9vVOkONF6WOmJ2G-Byejt8evD7yucIOnwygUntDWt5p8Fa2Yn16kdGtisu1Cq-Ik10ZqP9G-FIGh9cJGeZ4TJiwZS0YF2i_CHViv6so8AJS2kCKKwtykUkhy10Oaamtya-O02NfJAF6upi_THas5F9eYZr13UzWZ--8DeNY3_dxSefyp0d4KA1knzU0WMC9YTJZvOICn_WOSQz5cUZWpl9xGkCnIdIIDuN9ip--FOfr9KA1osA4if-8-ez85che7_970Cdw8OD4cZ-N3kw8P4VZAVlgbJLcH64v50jyC6_rLomzmjzv5-Anpohgr |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3da9RAEB_qVYovVVu1p1VXEfElYDabjwVfDuvhx3kUa6FvYbMfNHCXlMud0rf-B_rgX9i_xJlNLlhUEHxLyCQ7ZGd2ZnZnfgPwzCbUz0HHATccAxSpVaCUU4ExMdfSSVwzfaHwJJ1Os5MTebgBr9a1MC0-RL_hRprh12tScHtm3K9ajrOC5pmLa7ApqInMADYPPo2PJ_0pQip9Yw-fYC9FJjtkIZ_Js375qj36zcm86rN6ozO--X_s3oLtztlko1Y6bsOGrXZgd1RhoD0_Z8-ZT__0--o7sPWxO2XfhW-4gKzmzENduhJFBg0Tm1EUz_SpKiumGqbYAhmiuitGFfyU5LNgtWOn1PuzXCKfbElmEOWA6iSry4vvvmzGGqbm57O6NHVTNpcXP0bs6CtOPuv7nTDKF8WP2R6E-Q4cj998fv026Bo3BDqKIxEI7UKnMVbRivDpRYa3NkHfLnIqSQttpQ5THUrBLa4XLi6KAmXCobNkFdehie7CoKoruwdMOiNFHEeFzaSQGK5HIomcLZxLMvNSp0N4sZ6-XHeo5tRcY5b30U3V5P6_D-FpT3rWQnn8iWh_LQN5p81NzgkXLEHPNxrCk_4x6iEdrqjK1iuiEegKEpzgEO61stOPQhj9YZxxZNaLyN-Hz99Pj_zF_X8nfQxbhwfjfPJu-uEB3ODohLU5cvswWC5W9iFc11-WZbN41KnHT1PiF6Y |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Serum+neurofilament+light+chain+as+a+reliable+biomarker+of+hereditary+transthyretin%E2%80%90related+amyloidosis%E2%80%94A+Swiss+reference+center+experience&rft.jtitle=Journal+of+the+peripheral+nervous+system&rft.au=Loser%2C+Valentin&rft.au=Benkert%2C+Pascal&rft.au=Vicino%2C+Alex&rft.au=Pansy+Lim+Dubois+Ferriere&rft.date=2023-03-01&rft.pub=Wiley+Subscription+Services%2C+Inc&rft.issn=1085-9489&rft.eissn=1529-8027&rft.volume=28&rft.issue=1&rft.spage=86&rft.epage=97&rft_id=info:doi/10.1111%2Fjns.12524&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1085-9489&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1085-9489&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1085-9489&client=summon |